GENERAL2 Oct 2026
Hospital stocks: can strong demand offset regulatory risks? | Stock Market News
The Supreme Court questioned high mark-ups on cancer medicines on 22 September. It asked why the 16% trade margin on scheduled drugs cannot cover non-scheduled drugs. Hospital shares fell 8-12% since then. If a 16% cap comes in, one brokerage sees a 2-4% hit on margins, since medicines bring 20-25% of hospital revenue. The next hearing is on 12 October.
Key Statutory Highlights
- The Supreme Court asked the central government why the 16% trade margin applicable to scheduled drugs could not be extended to non-scheduled drugs.
- JM Financial Institutional Securities estimates a 2-4% hit on profit margins if the government caps trade margin at 16%.
- Shares of Global Health (Medanta), Apollo Hospitals Enterprise, Max Healthcare and Fortis Healthcare have declined 8-12% since 22 September.
Actionable Advice for Taxpayers / Founders:If you hold hospital stocks, note that the next court hearing is on 12 October and the government's stand on trade margins could affect prices. Speak to your advisor before acting on the news.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: